Menu Search
Equities

Pharmaust Ltd

PAAFF:PKC

Pharmaust Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded11.07k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jul 15 2024 13:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PharmAust Limited is a clinical-stage biotechnology company developing therapeutics for human and animal health applications. The Company’s segments include Corporate and Research. The Company is focused on repurposing monepantel (MPL) for human neurodegenerative diseases. The Company's lead candidate, Monepantel (MPL), is a potent and safe inhibitor of the mTOR pathway, that plays a central role in cell growth and proliferation of cancer cells and in degenerating neurons. The Company is also developing MPL as a treatment for motor neuron disease (MND/ALS), a rare, incurable disease. It is focused on starting Phase II/III clinical study of MPL. It has also completed a Phase II oncology clinical study of MPL in humans and pilot studies in canine cancer. It is also preparing a pivotal monepantel field trial in dogs with B-Cell Lymphoma to enable product registration in the United States.

  • Revenue in AUD (TTM)866.18k
  • Net income in AUD-8.90m
  • Incorporated2000
  • Employees52.00
  • Location
    Pharmaust Ltd96-100 Albert Road, Level 4SOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 39692-7222
  • Fax+61 89467-6111
  • Websitehttps://www.pharmaust.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.